A study [21] found that administering abemaciclib, which is a CDK4/6 inhibitor in the early stage of HR-positive/HER2-negative (HR+/HER2−) breast cancer, rather than waiting until patients develop metastatic disease, was a cost-effective treatment strategy. Here, ERBB2 is linked to breast carcinoma.